Science
Arthritis drug investigated as possible vascular dementia treatment
Scientists from the University of Sheffield and University of Manchester have been awarded £265,000 from the British Heart Foundation, to investigate the links between vascular dementia and heart disease, and test whether a drug currently used to treat arthritis could also be used as a treatment for vascular dementia.
Vascular dementia is caused by an impaired blood flow to the brain, symptoms of vascular dementia include confusion, concentration problems, and changes in mood and behaviour.
Heart disease is a known risk factor for vascular dementia, and preliminary research by the Sheffield scientists has shown that blood flow in the brain is substantially affected by heart disease. The new study will continue this research to examine in more detail how heart disease and vascular dementia interact together, potentially making the disease burden worse.
The project will also investigate an anti-inflammatory treatment to reduce inflammation in the brain and test whether this slows down, or reduces the severity of, vascular dementia.
New treatment hope
Led by Professor Sheila Francis, from the University of Sheffield, and working in collaboration with a team from the University of Manchester, the project brings together the disciplines of cardiovascular biology and pathology, neurovascular function and neuropathology.
Professor Sheila Francis said: “We noticed quite a few years ago that laboratory mice with severe atherosclerosis exhibited significant behaviour changes. On closer examination, their neurovascular function was altered, leading to the death of brain neurons and increased brain inflammation caused by a protein called interleukin-1.
“The study will compare this new model with the commonly used laboratory models of vascular dementia to investigate whether an anti-inflammatory drug against interleukin-1 already used successfully to treat arthritis and in clinical trials for use in stroke patients, could also improve neurovascular function in both cases.”
It is hoped the study will lead to anti-interleukin-1 therapies becoming a useful treatment for vascular dementia.
Dr Subreena Simrick, our Senior Research Adviser, said: “There is no cure for vascular dementia. Currently, all that doctors can do is prescribe drugs which can slow down its progression.
“By funding this research, we hope to take a step towards changing that and bring hope to people affected by this cruel disease.
“Unfortunately, our ability to fund important research like this is threatened by the impact of coronavirus on our fundraising. Now, more than ever, we need the support of the public so we can continue to support projects that could transform the lives of those with heart and circulatory diseases.”